Year: 2017
BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer
September 28, 2017
Bergen, Norway, Sep 28 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio ASA: Results for the Second Quarter and Half year 2017
August 18, 2017
Bergen, Norway, 18 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer – World R&D Summit in Boston
August 15, 2017
Bergen, Norway, July 26 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focussed…
Read MoreBerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer
June 26, 2017
Bergen, Norway, June 26 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017
June 6, 2017
Bergen, Norway, June 6 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing…
Read MoreBerGenBio ASA: Results for the First Quarter 2017
May 23, 2017
Bergen, Norway, 23 May 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159